Cell Signaling Technology

Product Pathways - Lymphocyte Signaling

SHIP2 Antibody #2730

Applications Reactivity Sensitivity MW (kDa) Source
W H Endogenous 160 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

SHIP2 Antibody detects the endogenous levels of total SHIP2 protein. It does not cross-react with SHIP1.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala1083 of human SHIP2. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of total cell lysates from SKMEL5 and HeLa cells, using SHIP2 Antibody.

Background

SH2-containing inositol phosphatase 1 (SHIP1) is a hematopoietic phosphatase that hydrolyzes phosphatidylinositol-3,4,5-triphosphate to phosphatidylinositol-3,4-bisphosphate (1). SHIP1 is a cytosolic phosphatase with an SH2 domain in its amino terminus and two NPXY Shc binding motifs in its carboxy terminus (1,2). Upon receptor cross-linking, SHIP is first recruited to the membrane junction through binding of its SH2 domain to the phospho-tyrosine in the ITIM motif (2), followed by tyrosine phosphorylation on the NPXY motif (2). The membrane relocalization and phosphorylation on the NPXY motif is essential for the regulatory function of SHIP1 (3-5). Its effect on calcium flux, cell survival, growth, cell cycle arrest and apoptosis is mediated through the PI3K and Akt pathways (3-5). Tyr1021 is located in one of the NPXY motifs in SHIP1, and its phosphorylation is important for SHIP1 function (6).

SHIP2, a homolog of SHIP1, is highly expressed in heart, skeletal muscle and placenta (7). SHIP2 negatively regulates insulin signaling (8) and polymorphisms in SHIP2 have been linked to hyperglycemia (9). Recent studies also suggest SHIP2 as a therapeutic target for the treatment of both obesity and type 2 diabetes (10,11).

  1. Tridandapani, S. et al. (1997) Mol Cell Biol 17, 4305-11.
  2. Liu, L. et al. (1997) J Biol Chem 272, 8983-8.
  3. Malbec, O. et al. (2001) J Biol Chem 276, 30381-91.
  4. Carver, D.J. et al. (2000) Blood 96, 1449-56.
  5. Scharenberg, A.M. et al. (1998) EMBO J 17, 1961-72.
  6. Sattler, M. et al. (2001) J Biol Chem 276, 2451-8.
  7. Pesesse, X. et al. (1997) Biochem. Biophys. Res. Commun. 239, 697-700.
  8. Wada, T. et al. (2001) Mol. Cell Biol. 21, 1633-1646.
  9. Ishida, S. et al. (2006) Pancreas 33, 63-67.
  10. Dyson, J.M. et al. (2005) Int. J. Biochem. Cell Biol. 37, 2260-2265.
  11. Sasaoka, T. et al. (2006) Pharmacol Ther 112, 799-809.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products